William Blair analyst Matt Phipps has maintained their neutral stance on MRUS stock, giving a Hold rating on October 7.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Matt Phipps’s rating is based on the anticipation surrounding the upcoming presentation of Merus’s Phase II data for petosemtamab in metastatic colorectal cancer at a major conference. The selection of this data for a plenary session has sparked renewed interest among investors, especially in light of the pending acquisition by Genmab. However, Phipps notes that historically, the significance of abstract selections at this conference has been mixed, as it often highlights first-in-class mechanisms that may not necessarily meet investor expectations for positive outcomes.
Despite the potential promise indicated by the plenary selection, Phipps remains cautious. He references past instances where similar presentations led to varied stock reactions, suggesting that while there is potential for upside, the outcomes are uncertain. This cautious stance, coupled with the historical context of mixed reactions to such announcements, underpins his decision to maintain a Hold rating on Merus’s stock.
In another report released on October 7, Leerink Partners also downgraded the stock to a Hold with a $97.00 price target.